The company's animal health division, MWI Animal Health, has entered a landmark fulfillment agreement with biotechnology firm Gallant. This partnership aims to create the first-ever ultra-low temperature cold chain for veterinary medicine. It is designed to support the delivery of what could be the first FDA-conditionally approved off-the-shelf veterinary stem cell therapy. This strategic move expands the company's role in the advanced veterinary therapeutics supply chain.